PRGO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades significantly below book value and sales, but lacks earnings quality.
- P/B 0.56
- P/S 0.39
- Negative earnings make P/E irrelevant
- Book value may be impaired
Growth metrics are consistently negative across revenue and earnings.
- Analyst target price suggests recovery potential
- Negative YoY revenue growth
- Crashing EPS growth (-3093.8%)
Long-term trend is aggressively bearish.
- 5-year price change of -66.5%
- Consistent failure to meet earnings estimates recently
F-Score indicates weak financial health despite current liquidity.
- Current Ratio 2.76
- Piotroski F-Score 2/9
- Negative ROE
Dividend is likely a candidate for a significant cut or suspension.
- High nominal yield (9.73%)
- Payout ratio of 10,950% is mathematically unsustainable
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PRGO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PRGO
Perrigo Company plc
Primary
|
-66.5% | -64.3% | -50.6% | -41.2% | +8.4% | +0.8% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-49.7% | +21.0% | -3.6% | -33.1% | -5.3% | +5.0% |
|
HRMY
Harmony Biosciences Holdings, Inc.
Peer
|
+0.6% | -8.8% | -0.3% | +8.8% | +0.3% | +4.2% |
|
NRIX
Nurix Therapeutics, Inc.
Peer
|
-47.4% | +33.4% | +65.5% | +77.6% | +6.0% | -0.3% |
|
INSP
Inspire Medical Systems, Inc.
Peer
|
-77.1% | -79.4% | -65.1% | -28.6% | +9.3% | +5.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PRGO
Perrigo Company plc
|
BEARISH | $1.64B | - | -38.7% | -33.5% | $11.92 | |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.67B | - | -30.2% | -% | $28.05 | Compare |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
NEUTRAL | $1.67B | 10.74 | 20.8% | 18.3% | $28.89 | Compare |
|
NRIX
Nurix Therapeutics, Inc.
|
NEUTRAL | $1.69B | - | -61.4% | -% | $16.3 | Compare |
|
INSP
Inspire Medical Systems, Inc.
|
BULLISH | $1.59B | 11.27 | 19.8% | 15.9% | $55.11 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | LOCKWOOD-TAYLOR PATRICK | Chief Executive Officer | Option Exercise | 17,834 | $193,499 |
| 2026-04-02 | BEZERRA EDUARDO GUARITA | Chief Financial Officer | Option Exercise | 6,369 | $69,104 |
| 2026-04-02 | WILLIS ROBERT | Officer | Option Exercise | 2,070 | $22,460 |
| 2026-03-06 | LOCKWOOD-TAYLOR PATRICK | Chief Executive Officer | Stock Award | 13,839 | $148,354 |
| 2026-03-06 | LOCKWOOD-TAYLOR PATRICK | Chief Executive Officer | Option Exercise | 11,727 | $125,713 |
| 2026-03-06 | SAMUELSON JONAS | Director | Option Exercise | 3,066 | $32,868 |
| 2026-03-06 | BEZERRA EDUARDO GUARITA | Chief Financial Officer | Stock Award | 22,208 | $238,070 |
| 2026-03-06 | BEZERRA EDUARDO GUARITA | Chief Financial Officer | Stock Award | 9,850 | - |
| 2026-03-06 | WILLIS ROBERT | Officer | Stock Award | 8,019 | $85,964 |
| 2026-03-06 | WILLIS ROBERT | Officer | Option Exercise | 4,501 | $48,251 |
| 2026-02-06 | LENNOX ABIGAIL | Officer | Option Exercise | 3,185 | $46,628 |
| 2025-11-12 | PARKER GEOFFREY M | Director | Purchase | 7,500 | $106,350 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
PRGO faces significant regulatory and trade risks, specifically regarding U.S. tariffs on imports from China and potential new tariffs targeting pharmaceuticals and OTC self-care products. Additional risks include volatility in import/export laws, extended payment cycles, and challenges operating in diverse political and cultural environments. Financial performance data was not provided in the available excerpts.
PRGO faces significant regulatory and trade risks, specifically regarding U.S. tariffs on imports from China and potential new tariffs targeting pharmaceutical and OTC self-care products. Additional risks include challenges with international payment cycles, shipping lead-times, and the enforcement of agreements in diverse political environments. Financial performance data was not provided in the available excerpts.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PRGO from our newsroom.